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We readwith great interest the case report by Lai et al1 in the
February 2012 issue of the Journal of the Formosan Medical
Association. The authors describe the clinical significance of
“Falsely decreased HbA1c in a type 2 diabetic patient treated
with dapsone”. In order to investigate the prevalence of
falsely low HbA1c in routine HbA1cmeasurement in a hospital
laboratory, we reviewed the electronic records of HbA1c
measurement during a 7-day period in March 2013.
In our laboratory we use boronate affinity chromatog-
raphy to measure total glycated hemoglobin (GHb) with the
Primus CLC 385 instrument (Primus diagnostics Trinity
Biotech Company, Berkeley Heights, NJ 07922, U.S.), and
HbA1c value (reference range, 3.8e6.0%) is converted from
total GHb (by equation: HbA1c Z 0.56  GHb þ 2.1). We
retrieved 3264 HbA1c results from our laboratory informa-
tion system in a 7-day period. Six patients had low HbA1c
(4.5e4.9%) levels. We then investigated their clinical in-
formation through the electronic medical record system of
our hospital to get the possible reasons for their low HbA1c
levels (Table 1). We found three patients with diabetes
mellitus, chronic kidney disease (CKD) stage 3e4 and ane-
mia, one patient with end-stage renal disease under regular
hemodialysis and anemia, one individual with human* Corresponding author. Department of Laboratory Medicine,
National Taiwan University Hospital, Number 7, Chung Shan South
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with no underlying disease.
HbA1c is useful in monitoring the glycemic control in
diabetics without CKD. HbA1c level is intimately correlated
with mean plasma glucose level and with microangiopathic
complications of diabetes mellitus.2 HbA1c is formed by
glycation (nonenzymatic glycosylation); glucose covalently
binds hemoglobin molecules in red blood cells (RBCs) in
circulating blood during its life span which is about 120 days
in a normal situation. HbA1c level depends on mean plasma
level of glucose, its rate-limiting step of glycation. In
addition, HbA1c level also depends on the life span of RBCs;
old RBCs carry more HbA1c than young ones. Several
pathologic conditions, such as hemolysis, dialysis, or severe
CKD (Stage 4 or 5; estimated glomerular filtration rate
<30 mL/min/1.73 m2) shorten RBC life span, and destroy
more old RBCs than young, leading to falsely low HbA1c
levels.3 Therefore the correlation between levels of HbA1c
and mean plasma glucose is different in diabetics with se-
vere CKD from without.3 Enhanced erythropoiesis, such as
under medication of erythropoietin (EPO) or iron supple-
ment, can produce more young RBCs, which also falsely
lowers HbA1c levels.
Medications, such as dapsone, can induce hemolysis,
which shortens the life span of RBCs and results in a falsely
low level of HbA1c. In our observation, four of six patients
with low HbA1c had CKD, anemia, and one under regular
hemodialysis. The cause of low HbA1c levels is probably a
shortened RBC life span in CKD with or without hemodial-
ysis. One patient was under EPO therapy, which stimulates
erythropoiesis, produces more young RBCs, and then
decreases HbA1c level further.& Formosan Medical Association. All rights reserved.
Table 1 Clinical information of the six patients with low HbA1c levels.
No. Age
(y)
Gender HbA1c
(%)
Glucose (mg/dL)
AC/PC
Clinical information Possible reason for
low HbA1c
1 37 Male 4.7 86 HIV infection
Lymphoma
Hb: 14.4 g/dL
Within normal limits
2 63 Male 4.9 88 DM
EPO usage, Hb: 10.1 g/dL
ESRD, eGFR: 9.6 mL/min/1.73 m2
CKD
EPO usage
3 83 Female 4.9 71/203 DM
CKD stage 3, eGFR: 41.6 mL/min/1.73 m2
Anemia, Hb: 8.6 g/dL
CKD
4 96 Male 4.5 139 DM
CKD stage 4, eGFR: 25.6 mL/min/1.73 m2
Anemia, Hb: 9.9 g/dL
CKD
5 37 Female 4.8 107 ESRD/HD, eGFR: 6.1 mL/min/1.73 m2
Anemia, Hb: 7.6 g/dL
CKD, dialysis
6 46 Male 4.9 85/85 Routine health examination Within normal limits
AC/PC Z antecibum (fasting)/postcibum (2 hours after meal); CKD Z chronic kidney disease; DM Z diabetes mellitus;
eGFRZ estimated glomerular filtration rate; EPOZ erythropoietin; ESRDZ end-stage renal disease; HDZ hemodialysis; HIVZ human
immunodeficiency virus.
Causes of decreased HbA1c levels 651Carbamylated hemoglobin, which results from urea
reacting with the hemoglobin molecule on the same site as
does glucose, may be an analytic issue for HbA1c mea-
surement by ion-exchange high-pressure liquid chromatog-
raphy method in patients with uremia. HbA1c values
measured by this method are falsely high in uremic patients
because the isoelectric point of carbamylated hemoglobin
is similar to that of HbA1c.4 In our laboratory, we perform
HbA1c by a different method, affinity chromatography,
which has less interference from carbamylated
hemoglobin.4
In summary, the interpretation of HbA1c should be
cautious on conditions altering RBC life span, such as
hemolysis, CKD, or EPO usage, which falsely decreases
HbA1c levels. Tests that are not altered by RBC life span,
such as fructosamine, glycated albumin, continuous
glucose monitoring, or self-monitoring blood glucosetests, may be suitable in these patients for glycemic
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